<DOC>
	<DOCNO>NCT01351350</DOCNO>
	<brief_summary>This Phase I , Open Label , Dose Escalation Study Oral Administration MLN0128 Combination With Paclitaxel , With/Without Trastuzumab , Subjects With Advanced Solid Malignancies</brief_summary>
	<brief_title>Dose Escalation Study MLN0128 Combination With Paclitaxel , With/Without Trastuzumab , Subjects With Advanced Solid Malignancies</brief_title>
	<detailed_description>This Phase I , open-label study consist dose escalation phase advance solid malignancy determine MTD oral administration MLN0128 1 dose schedule , combine paclitaxel Days 1 , 8 15 cycle , follow expansion phase safety preliminary efficacy . Once MTD determine dose schedule evaluate , dose schedule select expansion phase , may enroll subject 2 arm parallel : - Arm A consist HER2-/unknown cancer subject receive MLN0128+paclitaxel - Arm B consist HER2+ cancer subject receive MLN0128+paclitaxel plus weekly trastuzumab</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Voluntary write consent Locally advance metastatic solid tumor exception primary brain tumor , fail eligible standard care therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Ability swallow oral medication For woman childbearing potential , negative serum urine pregnancy test within 14 day prior first study drug administration use physicianapproved method birth control 30 day prior 30 day follow last study drug administration Male subject must surgically sterile must agree use physicianapproved contraception study 30 day follow last study drug administration Clinical laboratory value specify protocol For expansion phase ( Arm A ) HER2/unknown subject enrol For expansion phase ( Arm B ) HER2+ cancer subject enrol Diagnosis primary brain tumor Have receive prior cancer investigational therapy within 2 week prior first administration study drug Known impair cardiac function clinically significant cardiac disease Known treatment systemic corticosteroid within one week prior first administration study drug Diabetes mellitus HIV infection Known active cardiovascular disease condition specify protocol Pregnancy ( positive serum urine pregnancy test ) breast feed Malabsorption due prior gastrointestinal ( GI ) surgery , GI disease Other clinically significant comorbidities Please note additional inclusion exclusion criterion . The study center determine meet criterion . Site personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , site personnel explain reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Solid tumor , mTORC1/2 inhibitor , HER2</keyword>
</DOC>